314 related articles for article (PubMed ID: 15728870)
1. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells.
Brandler S; Brown N; Ermak TH; Mitchell F; Parsons M; Zhang Z; Lang J; Monath TP; Guirakhoo F
Am J Trop Med Hyg; 2005 Jan; 72(1):74-81. PubMed ID: 15728870
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction.
Johnson BW; Chambers TV; Crabtree MB; Guirakhoo F; Monath TP; Miller BR
Am J Trop Med Hyg; 2004 Jan; 70(1):89-97. PubMed ID: 14971704
[TBL] [Abstract][Full Text] [Related]
3. Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand.
Higgs S; Vanlandingham DL; Klingler KA; McElroy KL; McGee CE; Harrington L; Lang J; Monath TP; Guirakhoo F
Am J Trop Med Hyg; 2006 Nov; 75(5):986-93. PubMed ID: 17124001
[TBL] [Abstract][Full Text] [Related]
4. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
[TBL] [Abstract][Full Text] [Related]
5. Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes.
Johnson BW; Chambers TV; Crabtree MB; Bhatt TR; Guirakhoo F; Monath TP; Miller BR
Am J Trop Med Hyg; 2002 Sep; 67(3):260-5. PubMed ID: 12408664
[TBL] [Abstract][Full Text] [Related]
6. Construction and biological properties of yellow fever 17D/dengue type 1 recombinant virus.
Mateu GP; Marchevsky RS; Liprandi F; Bonaldo MC; Coutinho ES; Dieudonné M; Caride E; Jabor AV; Freire MS; Galler R
Trans R Soc Trop Med Hyg; 2007 Mar; 101(3):289-98. PubMed ID: 17169387
[TBL] [Abstract][Full Text] [Related]
7. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.
Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP
Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547
[TBL] [Abstract][Full Text] [Related]
9. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
[TBL] [Abstract][Full Text] [Related]
10. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.
Guirakhoo F; Arroyo J; Pugachev KV; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Soike K; Ratterree M; Monath TP
J Virol; 2001 Aug; 75(16):7290-304. PubMed ID: 11462001
[TBL] [Abstract][Full Text] [Related]
11. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.
Blaney JE; Sathe NS; Hanson CT; Firestone CY; Murphy BR; Whitehead SS
Virol J; 2007 Feb; 4():23. PubMed ID: 17328799
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.
Guirakhoo F; Pugachev K; Zhang Z; Myers G; Levenbook I; Draper K; Lang J; Ocran S; Mitchell F; Parsons M; Brown N; Brandler S; Fournier C; Barrere B; Rizvi F; Travassos A; Nichols R; Trent D; Monath T
J Virol; 2004 May; 78(9):4761-75. PubMed ID: 15078958
[TBL] [Abstract][Full Text] [Related]
13. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.
Guy B; Guirakhoo F; Barban V; Higgs S; Monath TP; Lang J
Vaccine; 2010 Jan; 28(3):632-49. PubMed ID: 19808029
[TBL] [Abstract][Full Text] [Related]
14. Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE).
Reid M; Mackenzie D; Baron A; Lehmann N; Lowry K; Aaskov J; Guirakhoo F; Monath TP
Am J Trop Med Hyg; 2006 Oct; 75(4):659-63. PubMed ID: 17038690
[TBL] [Abstract][Full Text] [Related]
15. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
16. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.
Guirakhoo F; Zhang Z; Myers G; Johnson BW; Pugachev K; Nichols R; Brown N; Levenbook I; Draper K; Cyrek S; Lang J; Fournier C; Barrere B; Delagrave S; Monath TP
J Virol; 2004 Sep; 78(18):9998-10008. PubMed ID: 15331733
[TBL] [Abstract][Full Text] [Related]
17. Growth characteristics of the veterinary vaccine candidate ChimeriVax-West Nile (WN) virus in Aedes and Culex mosquitoes.
Johnson BW; Chambers TV; Crabtree MB; Arroyo J; Monath TP; Miller BR
Med Vet Entomol; 2003 Sep; 17(3):235-43. PubMed ID: 12941006
[TBL] [Abstract][Full Text] [Related]
18. Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates.
McGee CE; Lewis MG; Claire MS; Wagner W; Lang J; Guy B; Tsetsarkin K; Higgs S; Decelle T
J Infect Dis; 2008 Mar; 197(5):693-7. PubMed ID: 18266603
[TBL] [Abstract][Full Text] [Related]
19. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14--14--2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes.
Bhatt TR; Crabtree MB; Guirakhoo F; Monath TP; Miller BR
Am J Trop Med Hyg; 2000 Apr; 62(4):480-4. PubMed ID: 11220763
[TBL] [Abstract][Full Text] [Related]
20. Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE).
Pugachev KV; Schwaiger J; Brown N; Zhang ZX; Catalan J; Mitchell FS; Ocran SW; Rumyantsev AA; Khromykh AA; Monath TP; Guirakhoo F
Vaccine; 2007 Sep; 25(37-38):6661-71. PubMed ID: 17693000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
